Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

12.93USD
4:02pm EDT
Change (% chg)

$-0.38 (-2.86%)
Prev Close
$13.31
Open
$13.22
Day's High
$13.33
Day's Low
$12.75
Volume
2,832,454
Avg. Vol
3,628,953
52-wk High
$32.74
52-wk Low
$8.32

Latest Key Developments (Source: Significant Developments)

Salix, Valeant and Actavis agree to stay outstanding litigation
Wednesday, 17 May 2017 07:00am EDT 

May 17 (Reuters) - Valeant :Statement regarding XiFaxan intellectual property litigation.Says Salix Pharmaceuticals, Valeant and Actavis Laboratories Inc, at Actavis' request, have agreed to stay outstanding litigation.Says companies have agreed to extend 30-month stay regarding Actavis' ANDA for a generic version of XiFaxan (Rifaximin) 550 mg tablets.Says legal action is stayed through April 30, 2018 and cannot be lifted prior to Oct. 31, 2017.Valeant says all currently scheduled litigation activities, including January 2018 trial date, have been indefinitely removed from court docket.  Full Article

Pershing Square Capital Management dissolves sole share stake in Valeant Pharmaceuticals
Monday, 15 May 2017 05:37pm EDT 

May 15 (Reuters) - Pershing Square Capital Management::Pershing Square Capital Management dissolves sole share stake in Valeant Pharmaceuticals International Inc - SEC filing.Change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Teva announces launch of generic Glumetza in the U.S.
Monday, 15 May 2017 01:20pm EDT 

May 15 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva announces launch of generic Glumetza® in the United States.Teva pharmaceutical says launch of generic Glumetza (metformin hydrochloride extended-release tablets), 500 mg and 1000 mg, in U.S..  Full Article

Valeant says may initiate additional cost savings programs to streamline its operations and eliminate redundant processes and expenses
Tuesday, 9 May 2017 06:18pm EDT 

May 9 (Reuters) - Valeant Pharmaceuticals International Inc [RIC:RIC:VPII.UL]:Valeant - Company continues to evaluate opportunities to improve its operating results and may initiate additional cost savings programs.Valeant says may initiate additional cost savings programs to streamline its operations and eliminate redundant processes and expenses.  Full Article

Valeant Pharmaceuticals reports Q1 GAAP earnings per share $1.79
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Valeant Pharmaceuticals International Inc : :Valeant - reduced debt by $1.3 billion in quarter.Valeant announces first quarter 2017 results and raises full year adjusted EBITDA guidance range.Q1 revenue $2.109 billion versus I/B/E/S view $2.18 billion.Q1 GAAP earnings per share $1.79.Q1 earnings per share view $0.87 -- Thomson Reuters I/B/E/S.Valeant - sees 2017 full year adjusted EBITDA (non-GAAP) in range of $3.60 - $3.75 billion from $3.55 - $3.70 billion.Valeant - total long term debt as of March 31, 2017 was $28,544 million versus. $29,846 million as of Dec. 31, 2016.  Full Article

Valeant reports debt reduction of about $220 mln
Monday, 1 May 2017 06:30am EDT 

May 1 (Reuters) - Valeant Pharmaceuticals International Inc ::Valeant announces additional debt reduction of approximately $220 million.Valeant - company has now reduced approximately $3.6 billion of debt from end of q1 2016.Valeant - has reduced its senior secured terms loans by approximately an additional $220 million as of monday may 1, 2017.Valeant - continues to advance toward expectation of paying down $5 billion in debt from divestiture proceeds, free cash flow within 18 months of august 2016.  Full Article

Bausch + Lomb gets 510(K) FDA clearance for vitesse
Wednesday, 26 Apr 2017 07:30am EDT 

April 26 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb receives 510(K) clearance from FDA for vitesse, the first and only hypersonic, open-port vitrectomy system.  Full Article

Valeant announces pricing for Siliq
Friday, 21 Apr 2017 07:30am EDT 

April 21 (Reuters) - Valeant Pharmaceuticals International Inc :Valeant's patient access and pricing committee announces pricing for Siliq(brodalumab) as the lowest priced injectable biologic for moderate-to-severe plaque psoriasis.Valeant - sales and marketing of Siliq are expected to commence in U.S. During second half of 2017.Valeant - decided to list Siliq injection, at $3,500 per month.Valeant - Siliq will also be included in company's patient access program to further offer financial support and access to patients.  Full Article

Bausch + lomb receives 510(k) clearance from FDA for stellaris elite next-generation phacoemulsification platform
Thursday, 6 Apr 2017 07:30am EDT 

Valeant Pharmaceuticals International Inc : Bausch + lomb receives 510(k) clearance from fda for stellaris elite™ next-generation phacoemulsification platform . Bausch + lomb receives 510(k) clearance from fda for stellaris elite™ next-generation phacoemulsification platform . Valeant - bausch + lomb plans to launch retina applications for stellaris elite this summer .Valeant - retina applications for stellaris elite will integrate both retina and cataract capabilities into a single machine.  Full Article

Bausch + Lomb Canada launches bepreve 1.5 pct w/v for allergic conjunctivitis
Wednesday, 22 Mar 2017 07:30am EDT 

Valeant Pharmaceuticals International Inc :Bausch + Lomb - Bausch + Lomb Canada launches bepreve (bepotastine besilate ophthalmic solution) 1.5 pct w/v for allergic conjunctivitis.  Full Article

More From Around the Web

BRIEF-EyeGate receives milestone payment from Valeant

* EyeGate receives milestone payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients